Valspodar
Jump to navigation
Jump to search
Valspodar (PSC833) is an experimental cancer treatment and chemosensitizer.[1] It is a derivative of ciclosporin D (cyclosporin D).
Its primary use is as an inhibitor of the efflux transporter P-glycoprotein. Previous studies in animal models have found it to be effective at preventing cancer cell resistance to chemotherapeutics, but these findings did not translate to clinical success.[2]
Adverse effects
Valspodar can cause nerve damage.[1]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".